Piramal Targets ADC and Semaglutide APIs to Drive CDMO Growth

Piramal Pharma is positioning its contract development and manufacturing operations around two of the highest-demand segments in the current pipeline landscape: antibody-drug conjugates and generic semaglutide active pharmaceutical ingredients. For plant heads and supply chain leads benchmarking capacity investments, the move signals where Indian CDMOs expect sustained volume pressure over the next planning cycle.

Chairperson Nandini Piramal told Reuters that the company is directing investment toward ADC manufacturing -- cancer therapies that link chemotherapy agents to antibodies -- and toward API production for generic semaglutides, driven by intense market demand for weight-loss drugs. Both categories carry significant GMP complexity: ADC manufacturing requires highly potent API containment infrastructure and rigorous sterility assurance controls, while semaglutide synthesis demands peptide manufacturing capabilities that remain capacity-constrained across the industry.

The strategic rationale reflects a broader pattern among Indian CDMOs seeking to move up the value chain beyond conventional small-molecule generics. ADC programs, governed under tightening ICH Q10 quality system expectations and 21 CFR Part 211 facility standards, require capital-intensive facility upgrades that smaller manufacturers cannot easily replicate. Piramal's declared focus on these segments suggests the company is targeting long-term supply agreements with innovator and generic sponsors who need qualified, high-containment manufacturing partners.

For QA directors and regulatory affairs leads evaluating CDMO partnerships, the expansion raises practical questions around process validation readiness, technology transfer timelines, and how Piramal's existing site network will be adapted or augmented to meet ADC-specific containment and handling requirements. Those details have not yet been disclosed publicly.

Source: Reuters, as reported by Pharmaceutical Industry News, April 29, 2026. Quotes and strategic direction attributed to Nandini Piramal, Chairperson, Piramal Pharma.